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IMPORTANCE The etiologic complexities of preterm birth remain inadequately understood,
which may impede the development of better preventative and treatment measures.
OBJECTIVE To examine the association between specific preterm-birth phenotypes and
clinical, growth, and neurodevelopmental differences among preterm newborns compared
with term newborns up to age 2 years.
DESIGN, SETTING, AND PARTICIPANTS The INTERBIO-21st study included a cohort of preterm
and term newborn singletons enrolled between March 2012 and June 2018 from maternity
hospitals in 6 countries worldwide who were followed up from birth to age 2 years. All
pregnancies were dated by ultrasonography. Data were analyzed from November 2019 to
October 2020.
EXPOSURES/INTERVENTIONS Preterm-birth phenotypes.
MAIN OUTCOMES AND MEASURES Infant size, health, nutrition, and World Health Organization
motor development milestones assessed at ages 1 and 2 years; neurodevelopment evaluated
at age 2 years using the INTERGROWTH-21st Neurodevelopment Assessment (INTER-NDA)
tool.
RESULTS A total of 6529 infants (3312 boys [50.7%]) were included in the analysis. Of those,
1381 were preterm births (mean [SD] gestational age at birth, 34.4 [0.1] weeks; 5148 were
term births (mean [SD] gestational age at birth, 39.4 [0] weeks). Among 1381 preterm
newborns, 8 phenotypes were identified: no main maternal, fetal, or placental condition
detected (485 infants [35.1%]); infections (289 infants [20.9%]); preeclampsia (162 infants
[11.7%]); fetal distress (131 infants [9.5%]); intrauterine growth restriction (110 infants
[8.0%]); severe maternal disease (85 infants [6.2%]); bleeding (71 infants [5.1%]); and
congenital anomaly (48 infants [3.5%]). For all phenotypes, a previous preterm birth was a
risk factor for recurrence. Each phenotype displayed differences in neonatal morbidity and
infant outcomes. For example, infants with the no main condition detected phenotype had
low neonatal morbidity but increased morbidity and hospitalization incidence at age 1 year
(odds ratio [OR], 2.2; 95% CI, 1.8-2.7). Compared with term newborns, the highest risk of
scoring lower than the 10th centile of INTER-NDA normative values was observed in the fine
motor development domain among newborns with the fetal distress (OR, 10.6; 95% CI,
5.1-22.2) phenotype.
CONCLUSIONS AND RELEVANCE Results of this study suggest that phenotypic classification
may provide a better understanding of the etiologic factors and mechanisms associated with
preterm birth than continuing to consider it an exclusively time-based entity.
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P reterm birth is a heterogeneous syndrome, which hasbeen previously described in terms of 3 factors: spon-taneous or medically induced labor, presence or ab-
sence of preterm premature rupture of membranes, and mode
of delivery.1 A phenotypic classification system, incorporat-
ing etiologically associated maternal, fetal, and placental char-
acteristics as well as signs of parturition and pathway to de-
livery, has also been proposed.2-4 Twelve preterm-birth
phenotypes (ie, separate biological entities with specific risk
factors, newborn anthropometry, and risk of neonatal mor-
bidity and mortality)5 have previously been identified. The
present INTERBIO-21st Newborn Study6 comprised phase 2 of
the International Fetal and Newborn Growth Consortium for
the 21st Century (INTERGROWTH-21st) Project, a population-
based research initiative involving almost 70 000 mothers and
infants worldwide that was conducted from 2008 to 2015. In
this study, we investigated whether preterm-birth pheno-
types were associated with clinical, epidemiological, growth,
and neurodevelopmental differences among preterm and term
infants up to age 2 years.
Methods
The INTERBIO-21st Newborn Study included a cohort of pre-
term and term newborns who were enrolled from March 2012
to June 2018 and followed up from birth to age 2 years. The
study was approved by the Oxfordshire Research Ethics Com-
mittee C, institutional research ethics committees at partici-
pating sites, and corresponding regional authorities. All moth-
ers provided written informed consent. This study followed
the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline for cohort studies.
Study Sites and Participants
The study was conducted in Pelotas, Brazil; Nairobi, Kenya;
Kilifi, Kenya; Karachi, Pakistan; Soweto, South Africa; Mae Sot,
Thailand; and Oxford, United Kingdom. The sites and study
populations have been described elsewhere.6
In brief, the study enrolled preterm newborns who were
live born at 23 weeks 0 days’ to 36 weeks 6 days’ gestation and
term newborns who were live born at 37 weeks 0 days’ to 41
weeks 6 days’ gestation.7 All newborns were naturally con-
ceived singletons with mothers who were age 18 years and older
and residing in the catchment area of the participating hospi-
tal. Gestational age was estimated by ultrasonographic mea-
surement of crown-rump length at less than 14 weeks 0 days’
gestation (75% of newborns) or head circumference at less than
24 weeks 0 days’ gestation (25% of newborns) using INTER-
GROWTH-21st standards.8,9 Given the design of the INTERBIO-
21st study, we selected a higher proportion of newborns with
lower birth weight (ie, < third centile).
Deliveries were screened daily using a tablet computer
(iPad; Apple),6 with software oversampling at lower gesta-
tional ages to increase statistical power for studying the high-
est-risk subgroups by producing a higher proportion of expo-
sures and adverse neonatal outcomes. To correct for the
oversampling of newborns who were small for gestational
age (defined as birth weight <10th centile based on INTER-
GROWTH-21st standards) in the present analysis, we gener-
ated a term newborn group consisting of term infants who were
appropriately grown for gestational age (defined as birth weight
≥10th centile based on INTERGROWTH-21st standards); ap-
proximately 10% of the term newborn group included ran-
domly selected term infants who were small for gestational age
to reflect the incidence of newborns who are small for gesta-
tional age in the general population.
Neonatal and Child Outcomes
The anthropometric measurement protocols, training mate-
rials, and quality control procedures were based on the World
Health Organization (WHO) Multicentre Growth Reference
Study,10 which produced the WHO Child Growth Standards.11
In brief, newborn measures were obtained within 12 hours of
birth (and no later than 24 hours after birth) using identical
equipment at all sites. An electronic scale (sensitivity,
10-20 g; Seca) was used to measure birth weight, and an in-
fantometer (Harpenden; Chasmors) was used to measure re-
cumbent length.10 Head circumference was measured using
metallic nonextendable tape (Chasmors). The anthropome-
trists independently took all measures twice and compared val-
ues using maximum allowable differences of 50 g for weight,
7 mm for length, and 4 mm for head circumference. If any dif-
ference exceeded those values, both observers indepen-
dently performed the relevant measurement a second time and,
if necessary, a third time.12,13 The Oxford Anthropometric
Standardization Unit regularly monitored staff performance
and recommended retraining if measurements consistently ex-
ceeded the maximum allowable differences.
Standardized care and feeding practices were imple-
mented using INTERGROWTH-21st protocols. Exclusive breast-
feeding until age 6 months was encouraged, with standard
supplementation for preterm newborns.14
Each mother provided detailed information about the in-
fant’s health and severe morbidities at birth, age 1 year, and
age 2 years using project-specific forms.15 We used an
unweighted composite neonatal outcome score comprising a
severe neonatal morbidity index that included 1 or more of the
Key Points
Question Are specific phenotypes in preterm newborns
associated with clinical, growth, and neurodevelopmental
differences at age 2 years compared with term newborns?
Findings In this cohort study of 6529 preterm and term
newborns who were followed up from birth to age 2 years, 8
preterm-birth phenotypes were identified: no main maternal,
fetal, or placental condition detected (35%); infections (21%);
preeclampsia (12%); fetal distress (10%); intrauterine growth
restriction (8%); severe maternal disease (6%); bleeding (5%);
and congenital anomaly (4%). Each phenotype was associated
with substantial differences in neonatal morbidity and infant
outcomes.
Meaning The study’s findings support the use of phenotypic
classification for preterm births.
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following severe neonatal complications: bronchopulmo-
nary dysplasia, hypoxic-ischemic encephalopathy, sepsis,
anemia (requiring transfusion), periventricular hemorrhage or
leukomalacia, retinopathy, necrotizing enterocolitis (Bell
stage 2 or higher), and patent ductus arteriosus (requiring
intervention).1,16-18 At ages 1 and 2 years, we assessed (1) hos-
pital admission (≥1 admission); (2) diagnosis and treatment for
infections requiring antibiotic medication (≥3 regimens), oti-
tis media, pneumonia, bronchiolitis, parasitosis, diarrhea, vom-
iting, exanthema, skin disease, fever lasting 3 or more days (≥3
episodes), and meningitis; (3) neurologic disorders, includ-
ing seizures and cerebral palsy; and (4) severe clinical condi-
tions, including cardiovascular problems, gastroesophageal
reflux, hemolytic conditions, trauma from injury, or any con-
dition requiring surgery.
At birth, we measured weight, length, and head circum-
ference following INTERGROWTH-21st protocols. At ages 1 and
2 years, we measured weight, length, and head circumfer-
ence following WHO protocols.10 Motor development was as-
sessed using the chronological age of the child by comparing
parental information with 4 WHO developmental mile-
stones: sitting without support, crawling on hands and knees,
standing alone, and walking alone.19
We assessed neurodevelopment at age 2 years using the
INTERGROWTH-21st Neurodevelopment Assessment (INTER-
NDA), which measures multiple dimensions of early develop-
ment among children aged 22 to 30 months.20 The INTER-
NDA is implemented by nonspecialists21 and uses mixed
methods to measure cognition, language development, fine
and gross motor skills, and positive and negative behavior. The
tool has been validated against the Bayley Scales of Infant
Development21,22 and has indicated good interrater and test-
retest reliability.20 Vision was assessed using the Cardiff
Visual Acuity and Contrast Sensitivity tests.23 We estimated the
proportion of children scoring lower than the 10th centile on
the INTER-NDA and on visual tests using international
standards.24
Statistical Analysis
To construct the preterm-birth phenotypes (eTable 1 in the
Supplement), we were guided by the work of the INTER-
GROWTH-21st Consortium, which provided a conceptual frame
and etiologic factors2-4 that were empirically tested.5 The same
definitions of maternal, fetal, and placental conditions and the
same analytical strategy using a 2-step cluster analysis (via the
2-step cluster algorithm in SPSS software, version 25; SPSS
Statistics) were then applied to the data collected for the
present study.5 This approach allowed us to compare the dis-
tribution of clusters and their proportional contribution across
populations.
Quality was assessed based on silhouette measures of co-
hesion and separation. Clustering was considered satisfac-
tory if the silhouette statistic was 0.6 or higher (range, −1.0 to
1.0).25 After the first analyses, we merged clusters associated
with infections (extrauterine infection, chorioamnionitis, and
perinatal sepsis) because each infection had low statistical
power when analyzed separately (eTable 1 in the Supple-
ment). Of 44 fetal anemia cases, cluster analysis categorized
28 cases (63.6%) as perinatal sepsis, 6 cases (13.6%) as mid to
late pregnancy, 5 cases (11.4%) as fetal distress, 3 cases (6.8%)
as preeclampsia, and 2 cases (4.5%) as congenital anomaly.
Because most cases were associated with perinatal sepsis, we
included those newborns in the infections group.
To assess associations between maternal risk factors and
phenotypes, we performed multinomial logistic regression
analyses to model nominal outcome variables. Odds ratios
(ORs) for each phenotype (and for all preterm newborns) com-
pared with the term newborn group were estimated based on
multinomial modeling. Model 1 was adjusted for maternal age,
height, first trimester and prepregnancy body mass index (cal-
culated as weight in kilograms divided by height in meters
squared), years of education, presence of prepregnancy men-
tal illness, length of menstrual cycle, and smoking during preg-
nancy. Model 2 was adjusted for all variables included in model
1 plus the number of previous pregnancies, miscarriages, and
terminations. Model 3 was adjusted for all variables included
in model 2 plus the number of previous births, low birth weight
(defined as <2500 g) and preterm infants, and neonatal deaths.
We found no data that violated the independence of irrel-
evant alternatives assumption in our models.
For all newborns, we generated age- and sex-specific z
scores for weight, length, head circumference, weight for
length, and percentage of newborns lower than the 10th cen-
tile compared with INTERGROWTH-21st standards7 and pre-
term reference charts.26 At ages 1 and 2 years, similar z scores
and centiles for weight, length, and head circumference were
generated compared with the WHO Child Growth Standards.11
We used 1-way analysis of variance to test whether the means
of each z score were different across the phenotypes and the
term newborn group. Phenotypic analyses at age 2 years used
chronological rather than corrected age.27
We performed logistic regression analysis to assess asso-
ciations between phenotypes and neonatal, 1-year, and 2-year
morbidity indices, presented as ORs with 95% CIs adjusted for
study site. For the neonatal morbidity analyses, we com-
pared individual preterm-birth phenotypes with the pheno-
type for no main maternal, fetal, or placental condition de-
tected. Unadjusted and adjusted analyses were conducted for
gestational age. Robust SEs were estimated in all logistic as-
sociation models using the vce (cluster clustvar) package in
Stata software, version 15 (StataCorp).
We used a Kruskal-Wallis nonparametric test to examine
the equality of age distribution at the achievement of gross mo-
tor development milestones among phenotypes and the term
newborn group. All analyses were performed using Stata soft-
ware, version 15. Data were analyzed from November 2019 to
October 2020.
Results
We prospectively enrolled 7540 women between 2012 and
2019; of those, 202 women were lost to follow-up or with-
drew consent. After excluding 27 infants with missing birth
weights, 7311 newborns (1381 preterm newborns and 5930 term
newborns; 4633 newborns who were appropriately grown for
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gestational age and 1297 newborns who were small for gesta-
tional age) remained (eFigure 1 in the Supplement). To re-
store the prevalence of infants who were small for gestational
age to 10%, we randomly excluded 782 term newborns who
were small for gestational age from the term newborn group.
After all exclusions, a total of 6529 infants (3312 boys [50.7%])
were included in the final analysis. Of those, 1381 newborns
were preterm births (mean [SD] gestational age at birth, 34.4
[0.1] weeks; mean [SD] maternal age, 29.3 [0.2] years) and 5148
newborns were term births (mean [SD] gestational age at birth,
39.4 [0] weeks; mean [SD] maternal age, 29.3 [0.1] years). The
overall follow-up rate was 78% (71% for preterm newborns and
80% for term newborns) at 1 year and 67% (64% for preterm
newborns and 68% for term newborns) at 2 years (eFigure 1
in the Supplement).
Each site’s contribution to the total study population
ranged from 7.6% (Karachi, Pakistan) to 25.0% (Oxford, United
Kingdom). For the preterm group, each site’s contribution
ranged from 6.7% (Soweto, South Africa) to 27.0% (Oxford,
United Kingdom). Sociodemographic characteristics were simi-
lar across groups from different sites.
Among 1381 preterm newborns, the largest phenotype was
no main maternal, fetal, or placental condition detected (no
main condition phenotype; 485 infants [35.1%]). Cluster se-
lection also derived phenotypes with 1 main condition (with
the exception of the severe maternal disease phenotype, com-
prising 85 infants [6.2%]), indicating that preterm birth was a
heterogeneous syndrome. These phenotypes comprised in-
fections (289 infants [20.9%]), preeclampsia (162 infants
[11.7%]), fetal distress (131 infants [9.5%]), intrauterine growth
restriction (110 infants [8.0%]), bleeding (71 infants [5.1%]), and
congenital anomaly (48 infants [3.5%]) (eTable 3 in the Supple-
ment). The main congenital anomalies diagnosed were in the
face, heart, and limbs, with no observable common factor.
Cesarean deliveries were more common among preterm
newborns compared with term newborns (696 of 1381 infants
[50.4%] vs 1778 of 5148 infants [34.5%], respectively) and
among preterm newborns with specific phenotypes, such as
preeclampsia (124 of 162 infants [76.5%]), bleeding (61 of 71 in-
fants [85.9%]), fetal distress (123 of 131 infants [93.9%]), and
severe maternal disease (55 of 85 infants [64.7%]) (eTable 2 in
the Supplement). Conditions such as preterm premature rup-
ture of membranes were more common among those with pre-
term-birth phenotypes for infections (174 of 289 infants
[60.2%]), severe maternal disease (32 of 85 infants [37.6%]),
and congenital anomaly (17 of 48 infants [35.4%]). In addi-
tion, newborns with preterm phenotypes had lower birth
weights (mean [SD], 2210 [15.9] g vs 3200 [6.2] g), shorter
length at birth (mean [SD], 44.6 [0.1] cm vs 48.9 [0] cm), smaller
head circumference at birth (mean [SD], 31.3 [0.1] cm vs 33.9
[0] cm), higher neonatal morbidity (eg, hospitalization in neo-
natal intensive care unit for >1 day, 755 of 1381 infants [54.7%]
vs 380 of 5148 infants [7.4%]), and higher neonatal mortality
(55 of 1381 infants [4.0%] vs 8 of 5148 infants [0.2%]) com-
pared with the term newborn group.
For all preterm-birth phenotypes, a previous preterm birth
was a risk factor for recurrence of preterm delivery (results for
each risk factor assessed in each model are available in eFig-
ure 2 in the Supplement). Associations with preterm pheno-
types were also identified, indicating a differential risk accord-
ing to preterm phenotype. The no main condition phenotype
was associated with young maternal age (OR, 1.6; 95% CI, 1.2-
2.2), nulliparity (OR, 2.0; 95% CI, 1.3-3.1), short maternal stat-
ure (OR, 1.4; 95% CI, 1.1-1.8), fewer maternal years of educa-
tion (OR, 1.5; 95% CI, 1.1-1.9), and 2 or more previous
miscarriages (OR, 1.5; 95% CI, 1.1-2.2). The preeclampsia phe-
notype was associated with low maternal body mass index (OR,
2.3; 95% CI, 1.0-4.9) or overweight maternal status (OR, 3.0;
95% CI, 2.1-4.5), nulligravidity (OR, 1.9; 95% CI, 1.3-3.0), and
delivery of a previous infant with low birth weight (OR, 2.8;
95% CI, 1.5-5.3). The infections phenotype was associated with
both younger (OR, 1.9; 95% CI, 1.3-2.9) and older (OR, 1.4; 95%
CI, 1.1-1.9) maternal age and previous termination of preg-
nancy (OR, 1.7; 95% CI, 1.1-2.8). The infections phenotype was
associated with both younger (OR, 1.9; 95% CI, 1.3-2.9) and older
(OR, 1.4; 95% CI, 1.1-1.9) maternal age and previous termina-
tion of pregnancy (OR, 1.7; 95% CI 1.1-2.8). The intrauterine
growth restriction phenotype was associated with short ma-
ternal stature (OR, 2.2; 95% CI, 1.3-3.8), smoking during preg-
nancy (OR, 5.0; 95% CI, 2.9-8.6), and previous miscarriages
(OR, 2.2; 95% CI, 1.2-3.9).
Newborn Size and Postnatal Growth
Overall, 249 preterm newborns (18.0%) were small for gesta-
tional age and most were associated with the intrauterine
growth restriction (73 infants [66.0%]), preeclampsia (42 in-
fants [26.1%]), and fetal distress (33 infants [24.9%]) pheno-
types (eFigure 3 in the Supplement).
Figure 1 presents anthropometric patterns from birth to age
2 years according to phenotype and for all preterm newborns
and the term newborn group, expressed as mean z scores (ac-
tual z score values are presented in eTable 4 in the Supple-
ment). Using z scores from birth to childhood was achievable
because international standards, constructed using the pre-
scriptive approach from the WHO,28 were available through-
out the childhood growth period. Figure 1A shows birth weight
distributed within 0 and −0.5 SD of the standards, with only
the intrauterine growth restriction phenotype substantially
lower than −1.0 SD. Beginning at age 1 year, 3 growth patterns
emerged. The first pattern, which was close to the WHO Child
Growth Standards 50th centile, consisted of the term new-
born group and preterm newborns with the bleeding, pre-
eclampsia, and severe maternal disease phenotypes. The
second pattern consisted of all preterm newborns plus those
with the no main condition, infections, and fetal distress phe-
notypes. The third pattern comprised newborns with the in-
trauterine growth restriction phenotype, which indicated a pat-
tern that was increasing but remained lower than −1.0 SD of
the WHO Child Growth Standards.11
Figure 1B presents the marked decrease in z scores for
length and height at age 1 year, with a mixed pattern at age 2
years. Height at age 2 years appeared less affected in the term
newborn group and in preterm newborns with some pheno-
types. Newborns with the bleeding phenotype remained close
to the 50th centile; those with the congenital anomaly and in-
trauterine growth restriction phenotypes were close to −1.0 SD
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of the WHO Child Growth Standards.11 Figure 1C shows a par-
allel pattern for postnatal head circumference growth among
phenotypes. By age 2 years, different gradients were ob-
served from newborns with the preeclampsia phenotype to the
term newborn group and preterm newborns with other phe-
notypes, including the no main condition phenotype. Figure 1D
shows patterns for birth weight, birth length, and postnatal
body mass index, expressed as z scores. Unlike the 3 patterns
in Figure 1A-C, similar trajectories were observed for all groups
higher than the 50th centile (ie, children started being over-
weight for their height by age 1 year).
Neonatal and Child Morbidity
Figure 2 shows ORs for neonatal severe morbidity by preterm-
birth phenotype compared with the no main condition phe-
notype. After adjusting for study site, all preterm-birth phe-
notypes had an increased risk of severe neonatal morbidity
compared with the no main condition phenotype. The re-
sults remained similar after adjustment for gestational age.
An analysis of each phenotype separately revealed con-
siderable heterogeneity. The highest risk of severe neonatal
morbidity was found in newborns with the infections (OR, 33.9;
95% CI, 11.6-98.9), bleeding (OR, 29.4; 95% CI, 9.6-90.6), and
congenital anomaly (OR, 27.1; 95% CI, 10.4-71.4) phenotypes.
The lowest risk of severe neonatal morbidity was observed in
newborns with the intrauterine growth restriction pheno-
type (OR, 9.7; 95% CI, 1.7-53.9); however, newborns with this
phenotype had the highest risk of neonatal and postnatal
growth restriction (Figure 1). There was minimal to no attenu-
ation in ORs for preterm-birth phenotypes compared with the
no main condition phenotype when adjusting for gestational
age (eg, for the infections phenotype, OR, 37.5 [95% CI, 11.9-
118.2]; for the bleeding phenotype, OR, 26.6 [95% CI, 7.8-
90.7]; and for the congenital anomaly phenotype, OR, 19.9 [95%
CI, 6.8-58.1]), indicating that underlying conditions were as-
sociated with increased morbidity independent of gesta-
tional age (Figure 2).
The phenotypes associated with different morbidities at
age 1 year among preterm newborns compared with the term
newborn group are shown in eTable 5 in the Supplement.
Excluding the congenital anomaly phenotype, newborns with
the no main condition (OR, 2.2; 95% CI, 1.8-2.7), infections (OR,
3.4; 95% CI, 2.3-5.2), and fetal distress (OR, 3.7; 95% CI, 2.4-
5.9) phenotypes had a higher risk of hospitalization. Those with
the preeclampsia (OR, 1.9; 95% CI, 1.5-2.6) and intrauterine
growth restriction (OR, 2.0; 95% CI, 1.2-3.3) phenotypes had
more infection-associated episodes. Newborns with the no
main condition (OR, 4.6; 95% CI, 2.1-9.8), bleeding (OR, 3.5;






































Mean weight for lengthD
























A-D, Mean values. Gestational age- and sex-specific centiles at birth were
compared with the international INTERGROWTH-21st newborn size standards
and reference charts for very preterm size at birth.7,25 Age- and sex-specific
centiles at ages 1 and 2 years were compared with the international World
Health Organization Child Growth Standards.26 P < .001 for all comparisons
based on analysis of variance. IUGR indicates intrauterine growth restriction;
NMCD, no main condition detected.
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95% CI, 1.2-10.2), intrauterine growth restriction (OR, 2.8; 95%
CI, 1.0-7.6), and fetal distress (OR, 4.4; 95% CI, 1.0-18.9) phe-
notypes had a higher risk of neurologic disorders, and those
with the infections (OR, 1.8; 95% CI, 1.3-2.4), bleeding (OR, 2.3;
95% CI, 1.2-4.3), and fetal distress (OR, 2.2; 95% CI, 1.7-2.8) phe-
notypes had a higher risk of severe clinical conditions.
Table 1 shows morbidity data at age 2 years. For infection-
associated episodes, the highest-risk phenotypes were fetal dis-
tress (OR, 1.8; 95% CI, 1.0-3.2), preeclampsia (OR, 1.5; 95% CI,
0.8-2.6), no main condition (OR, 1.4; 95% CI, 1.2-1.6), and se-
vere maternal disease (OR, 1.4; 95% CI, 1.0-2.2). For neuro-
logic disorders, the highest-risk phenotypes were preeclamp-
sia (OR, 6.9; 95% CI, 2.7-17.6) and fetal distress (OR, 3.0; 95%
CI, 1.0-9.1). For severe clinical conditions, the highest-risk
phenotype was severe maternal disease (OR, 1.9; 95% CI, 1.2-
3.1). As with newborn size and postnatal growth, considering
preterm birth as a single entity would have obscured the dif-
ferent morbidity patterns for each phenotype. Notably, there
was an increased risk of infections at age 2 years among pre-
term infants with the no main condition phenotype, a group
that is considered to have a low risk of adverse health out-
comes in childhood.
Neurodevelopmental Outcomes
Figure 3 presents the median age (with 25th-75th centiles) of
achievement for the WHO gross motor development mile-
stone of age at walking alone because this milestone is the least
subject to maternal recall bias and because our data could be
compared with the age ranges for achievement of WHO
milestones.29 Newborns with the phenotypes for intrauter-
ine growth restriction, bleeding, and congenital anomaly were
considerably slower in reaching this milestone, with median
ages at achievement of 15.0 months (25th-75th centile, 13.0-
18.0 months), 15.0 months (25th-75th centile, 13.0-17.0
months), and 15.2 months (25th-75th centile, 13.5-18.0 months),
respectively, representing a 3-month delay compared with the
median age of 12 months reported by the WHO.29 Newborns
with other phenotypes experienced a 1- to 2-month delay.
Table 2 presents the risk of scoring lower than the 10th cen-
tile of the normative population for the INTER-NDA domains24
according to phenotype and compared with the term new-
born group. Heterogeneity was observed, which would have
been missed if all preterm newborns had been considered as
a single entity. For example, excluding newborns with the con-
genital anomaly phenotype, those with the fetal distress phe-
notype had the highest risk of cognitive (OR, 5.1; 95% CI, 2.3-
11.1), fine motor (OR, 10.6; 95% CI, 5.1-22.2), gross motor (OR,
3.9; 95% CI, 1.8-8.5), and language (OR, 6.3; 95% CI, 3.2-12.2)
development problems. Newborns with the preeclampsia phe-
notype had a high risk of cognitive (OR, 2.7; 95% CI, 1.4-5.0),
fine motor (OR, 4.7; 95% CI, 1.2-18.3), and gross motor (OR, 4.1;
95% CI, 2.4-7.0) development problems. Compared with term
newborns, the highest risk of scoring lower than the 10th cen-
tile based on INTER-NDA normative values was observed in
the fine motor development domain among newborns with the
fetal distress (OR, 10.6; 95% CI, 5.1-22.2) and congenital
anomaly (OR, 31.1; 95% CI, 3.2-300.3) phenotypes. The risk of
fine motor delay was high among all preterm-birth pheno-
types.
Discussion
The study’s findings indicated that, among an international
sample selected to maximize the inclusion of high-risk preg-
nancies, differential patterns existed with regard to maternal
risk factors, the incidence of newborns who were small for ges-
tational age, neonatal and childhood growth, neonatal and
childhood severe morbidity, and neurodevelopment across pre-
term-birth phenotypes. These differential patterns are likely
associated with specific pathologic factors that have implica-
tions for the growing fetus, as previously reported for early neo-
natal outcomes.5
The postnatal patterns varied across phenotype and age.
For example, newborns with the intrauterine growth restric-
tion phenotype had lower neonatal morbidity but more growth
restriction and neurodevelopmental delay in childhood. New-
borns with the no main condition phenotype who were not
small for their gestational age had lower neonatal morbidity
but increased morbidity at age 2 years. Those with the infec-
tions phenotype had lower gestational ages at birth and a low
risk of being small for gestational age but a high risk of mor-
bidity and postnatal growth restriction.
The association between preterm birth and the pheno-
type for intrauterine growth restriction, which was observed
in 8.0% of all preterm infants, would not have emerged had
Figure 2. Severe Neonatal Morbidity Index According to Preterm-Birth
Phenotype
1 16 1284 328 64










Adjusted for study site
Adjusted for study site and gestational age
The Severe Neonatal Morbidity Index includes bronchopulmonary dysplasia,
hypoxic-ischemic encephalopathy, sepsis, neonatal anemia (requiring
transfusion), periventricular hemorrhage or leukomalacia, retinopathy of
prematurity, necrotizing enterocolitis (Bell stage 2 or higher), and patent ductus
arteriosus (requiring pharmacologic treatment or surgery). There were no cases
of severe neonatal morbidity in newborns with the severe maternal disease
phenotype. Odds ratios are based on comparisons with the NMCD phenotype.
The 95% CIs were based on robust SEs. IUGR indicates intrauterine growth
restriction; NMCD, no main condition detected.
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the syndrome’s heterogeneity not been recognized. Notably,
some preterm newborns with the intrauterine growth restric-
tion phenotype were not included in that phenotype group for
this study because they had other pathologic characteristics,
such as preeclampsia or congenital anomalies. Other etio-
logic factors were likely associated with fetal growth restric-
tion (eFigure 2 in the Supplement).1
Our results support clustering 1 or more maternal, fetal,
or placental conditions to construct phenotypes rather than
relying on 1 associated factor. However, 35.1% of preterm births
were clustered in the no main condition phenotype, which
likely reflects reliance on the use of clinical parameters alone
for classification or suggests more complex underlying asso-
ciations between environmental and nutritional factors.
In this study, the dominant pathologic characteristics in
the remaining phenotypes (3 maternal, 3 fetal, and 1 placental)2
commonly occurred with complications and comorbidities
(particularly extrauterine infection, chorioamnionitis, and peri-
natal sepsis) that were associated with the dominant condi-
tion and preterm birth (eTable 3 in the Supplement). Never-
theless, there are sufficient data to justify targeting the main
putative conditions for the prevention and clinical manage-
ment of these preterm-birth phenotypes.
The present study is distinct because (1) it has a firm con-
ceptual basis2-4; (2) it was designed to explore a priori hypoth-
eses associated with the heterogeneity of preterm birth; (3) it
accurately estimated gestational age in all newborns; (4) it over-
sampled newborns with low gestational ages to maximize the
Table 1. Morbidity Among Children at Age 2 Years According to Preterm-Birth Phenotypea
Variable
Children with ≥1 hospitalization
Children diagnosed with
or treated for ≥3 infections
Children diagnosed with
or treated for neurologic
disorders
Children diagnosed with
or treated for severe clinical
conditions
No./
total No. (%) OR (95% CI)
No/
total No. (%)b OR (95% CI)b
No./
total No. (%)c OR (95% CI)c
No./




40/287 (13.9) 1.4 (1.1-1.8) 47/287 (16.4) 1.4 (1.2-1.6) 7/287 (2.4) 2.2 (0.8-5.8) 25/287 (8.7) 0.8 (0.5-1.3)
Preeclampsia 9/92 (9.8) 1.1 (0.3-3.6) 17/92 (18.5) 1.5 (0.8-2.6) 7/92 (7.6) 6.9
(2.7-17.6)
11/92 (12.0) 1.1 (0.6-1.9)
Infections 25/150 (16.7) 1.6 (1.2-2.0) 16/150 (10.7) 1.1 (0.4-3.0) 4/150 (2.7) 2.4 (0.7-8.5) 13/150 (8.7) 0.8 (0.5-1.1)
Bleeding 9/44 (20.5) 2.3 (1.5-3.4) 6/44 (13.6) 1.4 (0.4-4.4) 0/44 (0) NA 2/44 (4.5) 0.4 (0.2-0.8)
Intrauterine growth
restriction
12/47 (25.5) 3.1 (1.6-6.0) 4/47 (8.5) 0.9 (0.2-3.3) 1/47 (2.1) 1.7
(0.2-13.3)
7/47 (14.9) 1.6 (0.5-5.1)
Fetal distress 17/76 (22.4) 2.7 (1.6-4.5) 12/76 (15.8) 1.8 (1.0-3.2) 3/76 (3.9) 3.0 (1.0-9.1) 10/76 (13.2) 1.5 (0.9-2.6)
Severe maternal
disease
8/55 (14.5) 1.7 (0.8-3.6) 10/55 (18.2) 1.4 (1.0-2.2) 1/55 (1.8) 1.4 (0.4-5.3) 11/55 (20.0) 1.9 (1.2-3.1)
Congenital anomaly 7/29 (24.1) 2.5 (1.0-6.2) 3/29 (10.3) 1.1 (0.6-2.3) 1/29 (3.4) 2.7
(0.3-23.5)
12/29 (41.4) 6.0 (3.7-9.7
All preterm newborns 127/780 (16.3) 1.7 (1.4-2.0) 115/780 (14.8) 1.4 (1.1-1.7) 23/780 (3.0) 2.5 (1.3-4.7) 91/780
(11.7)
1.1 (0.9-1.4)









Abbreviations: NA, not applicable; OR, odds ratio.
a Adjusted for study site. 95% CIs are based on robust SEs.
b Infections include treatment with antibiotic medication (3 regimens), otitis
media, pneumonia, bronchiolitis, parasitosis, diarrhea, vomiting, exanthema,
skin disease, fever lasting 3 days or more (3 episodes), meningitis, and other
infections that required antibiotic treatment.
c Neurologic disorders include seizures, cerebral palsy, and other neurologic
disorders.
d Severe clinical condition includes cardiovascular problems, gastroesophageal
reflux, any hemolytic condition, injury trauma, and any condition that required
surgery.
Figure 3. Median Age for Developmental Achievement of Walking Alone According to Preterm-Birth Phenotype















interquartile ranges. For comparison,
the 25th and 75th centiles of the
WHO periods of achievement for the
same developmental milestone29 are
shown in the shaded area (with the
median age represented by a broken
vertical line). IUGR indicates
intrauterine growth restriction;
NMCD, no main condition detected;
and WHO, World Health
Organization.
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number of subgroups considered very high risk; (5) it achieved
a 1:4 ratio for enrolled preterm and term newborns, substan-
tially exceeding the 1:1 target; (6) it monitored growth, mor-
bidity, and neurodevelopment from birth to age 2 years using
standardized data collection systems; and (7) it assessed neu-
rodevelopment compared with international normative val-
ues using a validated psychometric tool.24,30
The study’s results have implications for research and clini-
cal practice. Preterm birth is a distinct syndrome in the medi-
cal field because it is defined by time (ie, gestational age at birth
rather than etiologic, clinical, nutritional, or laboratory char-
acteristics, as with other syndromes). Hence, it is important
to estimate the gestational age as accurately as possible, con-
sistent with the 2016 WHO guidelines,31 and to avoid the use
of low birth weight (ie, <2500 g regardless of gestational age)
as a factor.32 It has been asserted that low birth weight is a nec-
essary factor to include because, in many regions of the world,
gestational age cannot be reliably estimated. However, ac-
tions to minimize the incidence of preterm birth may none-
theless be taken and are warranted for a syndrome that oc-
curs in at least 10% to 12% of all births worldwide and has
serious implications for human developmental capacity. Gov-
ernments, international organizations, and donors can work
to improve antenatal care so that every woman receives ad-
equate evaluation early in pregnancy.31
Limitations
This study has several limitations. The loss to follow-up at age
2 years was higher than that of previous studies,30,33 as some
sites were located in rural or semiurban areas. This limitation
was considered when the INTERBIO-21st study was de-
signed, but we concluded that the loss of follow-up at such sites
was offset by the enrollment of a high-risk population with ac-
curate gestational ages and a higher number of more severe
exposures (eg, infections and inadequate nutrition). Never-
theless, the risk of systematic loss to follow-up bias according
to phenotype is unlikely because, with the exception of the in-
trauterine growth restriction phenotype, the follow-up rates
across phenotypes were similar.
We could not include multiple births because we fo-
cused, for several logistical and sample size reasons, on single-
tons. In addition, we did not include stillbirths or late termi-
nations because the childhood follow-up component was
fundamental to the study. We also did not document the ways
in which urinary tract infections were specifically diagnosed
or record whether prophylactic antibiotic medications were
prescribed for the treatment of group B streptococcus coloni-
zation. We categorized congenital anomaly as a separate phe-
notype to reinforce the integrity of preterm birth as a distinct
syndrome. However, given the small sample of infants with
the congenital anomaly phenotype (3.5% of all preterm new-
borns), we could not draw meaningful conclusions.
Although cluster methods are susceptible to nuances in the
data, the fact that we obtained clusters that were similar to
those acquired in a previous study,5 using identical methods
but a data set with a different risk profile, supports our hy-
pothesis that these phenotypes occur systematically across
populations. However, the phenotype prevalence changes de-
pending on which factors predominate.
We recognize that there are competing etiologic charac-
teristics and risk factors among the preterm birth, intrauter-
ine growth restriction, and stillbirth syndromes,34 which were
highlighted by Lee et al.35 Our study was designed to explore
the preterm and intrauterine growth restriction syndromes
in parallel. This overlapping approach was required because
intrauterine growth restriction is an equally complex syn-
drome that has multiple etiologic characteristics and presen-
tations. However, our focus on developmental outcomes
Table 2. Risk of Scoring Lower Than the 10th Centile on the INTERGROWTH-21st Neurodevelopment Assessment at Age 2 Years















252 2.0 (1.6-2.5) NA 1.2 (0.4-3.4) 1.6 (0.8-3.2) 1.3 (1.1-1.7) 1.3 (1.1-1.6)
Preeclampsia 84 2.7 (1.4-5.0) 4.7 (1.2-18.3) 4.1 (2.4-7.0) 1.2 (0.8-1.8) 1.4 (0.9-2.2) 2.0 (1.3-3.1)
Infections 129 1.6 (0.7-3.4) 5.1 (1.7-15.4) 2.6 (1.4-4.9) 2.0 (0.8-5.1) 1.1 (0.8-1.7) 1.5 (1.3-1.7)
Bleeding 42 0.5 (0.1-2.9) NA 2.9 (1.2-7.2) NA 0.1 (0.0-0.6) 0.6 (0.2-1.6)
Intrauterine growth
restriction
45 0.5 (0.1-4.9) NA 2.0 (1.3-3.1) 1.2 (0.4-3.8) 1.5 (0.9-2.5) 1.4 (0.8-2.3)
Fetal distress 67 5.1 (2.3-11.1) 10.6 (5.1-22.2) 3.9 (1.8-8.5) 6.3 (3.2-12.2) 1.7 (0.7-3.7) 1.6 (0.9-2.8)
Severe maternal disease 51 2.1 (1.0-4.4) 3.9 (2.8-5.6) 0.6 (0.2-1.9) 2.4 (1.0-5.8) 1.9 (1.1-3.5) 1.3 (0.5-3.5)
Congenital anomaly 27 5.6 (1.9-16.2) 31.1 (3.2-300.3) 6.6 (0.8-57.2) 7.2 (0.6-86.8) 2.8 (1.0-8.2) 3.0 (1.3-6.6)
All preterm newborns 697 2.2 (1.6-3.0) 4.2 (1.7-9.9) 2.2 (1.4-3.5) 2.1 (1.3-3.3) 1.3 (1.2-1.5) 1.4 (1.3-1.6)
Term newborn group 2965 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
Abbreviations: INTERGROWTH-21st, International Fetal and Newborn Growth
Consortium for the 21st Century; NA, not applicable; OR, odds ratio.
a Adjusted for study site. 95% CIs are based on robust SEs.
b Negative behavior is defined as a risk of negative behavior that scored higher
than the 90th centile on the INTERGROWTH-21st Neurodevelopment
Assessment at age 2 years according to preterm-birth phenotype compared
with the term newborn group.
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precluded including stillbirths. Future research may explore
these associations in detail.
Conclusions
In this study, the preterm birth syndrome was composed of
well-defined phenotypes with differential neonatal morbid-
ity, early childhood morbidity, growth, and neurodevelop-
ment up to age 2 years. Therefore, the concept of preterm birth
as an exclusively time-based entity may no longer be appro-
priate. Phenotypic classification of preterm newborns is likely
to provide a better understanding of the etiologic factors and
mechanisms associated with preterm birth. Although the
study’s findings indicated that approximately 35% of pheno-
types were not associated with distinct clinical conditions, new-
borns with preterm-birth phenotypes nevertheless remain at
a higher risk of growth and developmental problems.
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